Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) anticipates data from Phase 3 NOVA trial of Niraparib in patients with ovarian cancer in Q2 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%

Additional Information

Additional Relevant Details This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent.
https://clinicaltria...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 29, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Niraparib, Parp Inhibitors, Phase 3 Results, Ovarian Cancer